Trial Profile

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine adjuvanted Novavax (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms SHIELD
Sponsors Novavax

Most Recent Events

02 Jun 2026 Status changed from active, no longer recruiting to completed.
15 Apr 2025 According to Novavax media release, preliminary results from this study were presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025.
15 Apr 2025 Preliminary Results published in the Novavax Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com